NASDAQ · INVA
Healthcare · Biotechnology
$21.28
Down-$0.37 (-1.74%)
Updated Oct 21, 2026, 8:43 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · INVA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
INVA closed at $21.28 after 21 trading sessions, up 1.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $21.31 | $21.49 | $21.12 | $21.28 | 507.56K |
| Oct 19, 2026 | $20.68 | $21.15 | $20.68 | $21.08 | 590.51K |
| Oct 16, 2026 | $20.97 | $20.97 | $20.556 | $20.78 | 550.49K |
| Oct 15, 2026 | $21.33 | $21.76 | $20.83 | $20.86 | 672.98K |
| Oct 14, 2026 | $20.79 | $21.18 | $20.73 | $20.97 | 673.51K |
| Oct 13, 2026 | $21.55 | $21.55 | $20.705 | $20.74 | 811.94K |
| Oct 12, 2026 | $21.27 | $21.48 | $21.12 | $21.45 | 521.19K |
| Oct 9, 2026 | $20.80 | $21.28 | $20.78 | $21.21 | 507.58K |
| Oct 8, 2026 | $21.05 | $21.05 | $20.73 | $20.87 | 612.35K |
| Oct 7, 2026 | $20.78 | $21.10 | $20.78 | $21.06 | 636.39K |
| Oct 6, 2026 | $20.78 | $20.97 | $20.62 | $20.83 | 679.63K |
| Oct 5, 2026 | $20.53 | $20.735 | $20.45 | $20.64 | 993.39K |
| Oct 2, 2026 | $20.60 | $20.76 | $20.495 | $20.50 | 774.71K |
| Oct 1, 2026 | $21.28 | $21.28 | $20.53 | $20.55 | 927.09K |
| Sep 30, 2026 | $21.11 | $21.45 | $21.06 | $21.21 | 1.1M |
| Sep 29, 2026 | $21.19 | $21.19 | $20.74 | $21.11 | 555.81K |
| Sep 28, 2026 | $20.74 | $21.39 | $20.59 | $21.23 | 854.63K |
| Sep 25, 2026 | $20.70 | $20.78 | $20.35 | $20.74 | 623.37K |
| Sep 24, 2026 | $20.28 | $20.79 | $20.28 | $20.66 | 1.37M |
| Sep 23, 2026 | $21.11 | $21.36 | $20.23 | $20.24 | 4.03M |
| Sep 22, 2026 | $21.17 | $21.39 | $20.96 | $20.98 | 931.64K |
The latest Smart Investors Daily articles mentioning INVA.
Company
Market Activity
Research & News
INVA research
Company profile and research snapshot.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 22, 2026 | BTIG | Buy | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
| May 26, 2026 | BTIG | Buy | — |
| May 7, 2026 | BTIG | Buy | — |
Generated Oct 21, 2026, 5:08 PM
Innoviva Inc shares declined 1.17% today, reflecting a modest pullback despite recent positive developments in the company's pipeline. The sell-off appears modest and lacks a specific negative catalyst, suggesting profit-taking or broader market headwinds rather than company-specific concerns. Recent announcements about upcoming clinical data presentations and valuation optimism from analysts haven't been enough to sustain upward momentum.
Bottom line: INVA's 1.17% decline appears to be a minor pullback without major negative catalysts, and the stock trades at what analysts view as an undervalued earnings multiple with near-term clinical data catalysts on the horizon. Investors should monitor the upcoming IDWeek 2026 presentations closely, as positive infectious disease portfolio data could validate the current valuation and drive upside momentum. The key risk remains execution on clinical trials and competitive dynamics in specialty therapeutics.
ChartMill · Oct 20, 2026
Innoviva (INVA) fits the Decent Value screen with low valuation, strong balance sheet, high margins, and attractive growth potential for value investors.
Yahoo · Oct 19, 2026
WALTHAM, Mass., October 19, 2026--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Conventio
Yahoo · Oct 12, 2026
Investors need to pay close attention to INVA stock based on the movements in the options market lately.
Yahoo · Oct 8, 2026
Innoviva (INVA) has drawn fresh attention after Zacks highlighted the stock as a strong value pick. The firm pointed to its A grade for Value as well as its relative P/E and cash flow metrics. Recent trading has been mixed for Innoviva, with the share price at US$21.06 after a modest 1-day share price gain of 1.10%. However, the 90-day share price return is down 5.14% and short-term momentum has eased, even as the 1-year total shareholder return of 21.24% and 3-year total shareholder return...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INVA.
